Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure

40Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

Abstract

L-3,4-dihydroxypheylalanine (L-dopa)-induced dyskinesia represent a debilitating complication of therapy for Parkinson's disease (PD) that result from a progressive sensitization through repeated L-dopa exposures. The MPTP macaque model was used to study the proteome in dopamine-depleted striatum with and without subsequent acute and chronic L-dopa treatment using two-dimensional difference in-gel electrophoresis (2D-DIGE) and mass spectrometry. The present data suggest that the dopamine-depleted striatum is so sensitive to de novo L-dopa treatment that the first ever administration alone would be able (i) to induce rapid post-translational modification-based proteomic changes that are specific to this first exposure and (ii), possibly, lead to irreversible protein level changes that would be not further modified by chronic L-dopa treatment. The apparent equivalence between first and chronic L-dopa administration suggests that priming would be the direct consequence of dopamine loss, the first L-dopa administrations only exacerbating the sensitization process but not inducing it.

Cite

CITATION STYLE

APA

Scholz, B., Svensson, M., Alm, H., Sköld, K., Fälth, M., Kultima, K., … Andrén, P. E. (2008). Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure. PLoS ONE, 3(2). https://doi.org/10.1371/journal.pone.0001589

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free